Sean Sterrenberg
Orthopaedic Surgery · Reno, NVNPI 1740642495
Payments from drug & device makers
What this record shows
This record is dominated by education: $15,146 of the $23,260 with a category attached, or 65.1%. Smith+Nephew accounts for 65.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $9,340 and has fallen 95.4% since, to $425 in 2025.
Across 63 payments — averaging $369.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$15K
- Zimmer Biomet$8K
- Vertex$44
- Stryker$32
- Orthofix Medical, Inc.$25
- Medline Industries LP$15
What the payments were for
- Travel & lodging$5,87425%
- Food & beverage$2,23910%
- Education$15,14665%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 7 | $15,250 |
| Zimmer Biomet | 51 | $7,893 |
| Vertex | 2 | $44 |
| Stryker | 1 | $32 |
| Orthofix Medical, Inc. | 1 | $25 |
| Medline Industries LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Persona$2,431
- Avenir$2,207
- G7$840
- ROSA$652
- Comprehensive Shoulder System$157
How this compares
$23,260 in reported general payments places this provider in the 80th percentile of 135 orthopaedic surgery providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 145 | $1,486 |
| Methocarbamol | 125 | $1,055 |
| Naloxone Hcl | 15 | $1,047 |
| Tramadol Hcl | 252 | $943 |
| Oxycodone Hcl | 181 | $870 |
| Celecoxib | 40 | $689 |
| Naproxen | 114 | $629 |
| Tranexamic Acid | 28 | $530 |
| Omeprazole | 87 | $474 |
| Meloxicam | 79 | $249 |
| Doxycycline Hyclate | 12 | $215 |
| Methylprednisolone | 31 | $205 |
| Amoxicillin | 93 | $203 |
| Clindamycin Hcl | 19 | $29 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Reno
- Hilary MalcarneyReno$189K
- Travis KieckbuschReno$54K
- Sean FitzpatrickReno$28K
- Babe WestlakeReno$17K
- Patrick BarousseReno$14K
- Mark BarryLas Vegas$9.5M
- Erik KubiakLas Vegas$7.8M
- Russell NevinsLas Vegas$1.5M
- Vladimir SinkovLas Vegas$434K
- Robert TaitHenderson$365K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.